comparemela.com

Esmo 2023 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ESMO 2023 Updates in Endometrial and Cervical Cancer Give Glimpse Into Future Care

Updated data from several clinical trials in both endometrial and cervical cancer could signal the emergence of multiple effective treatment options coming down the pike.

Sri lankaUnited statesDavidm omalleyGonzalez martinGallardo rincOnclive peer exchangeEuropean society for medical oncologyHispanic blackEuropean societyMedical oncologyAdvanced recurrent endometrialRecurrent metastatic cervicalPrescription drug user feeTransduct targetEsmo 2023

Bladder Cancer: Highlights from ESMO 2023 and Ongoing Developments

The expert panel reviews highlights from ESMO 2023 and discusses ongoing developments in the treatment landscape for bladder cancer.

Bladder cancerNon muscle invasive bladder cancerEsmo 2023Highlights from esmo 2023Molecular biomarkers

Diagnosing and Staging Patients With Endometrial Cancer

Expert gynecologic oncologists discuss recent progress in treating advanced endometrial and cervical cancers, including epidemiology, risk factors, evaluation, staging, and molecular testing.

Recent advancesTreating endometrialCervical cancersStaging patients with endometrialGynecologic cancersEsmo 2023Endometrial cancerEndometrial carcinomaCervical cancerUterine cancerEndometrial cancer treatmentsEndometrial cancer treatment updatesCervical cancer treatmentsCervical cancer treatment updates

Randomized Phase 3 Study of First-line Selpercatinib vs Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC: LIBRETTO-431

Expert oncologist Benjamin Levy, MD, shares data from the LIBRETTO-431 trial comparing selpercatinib to chemotherapy plus pembrolizumab in RET fusion-positive NSCLC following ESMO 2023.

Benjamin levyRandomized phaseFirst line selpercatinibPartnership withNon small cell lung cancerLung cancerLibretto 431Chemo ioSafety dataEfficacy dataAdverse eventsToxicity profilePfs dataOverall survival dataEsmo 2023Esmo congress

Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy for Patients with Metastatic HR+/HER2– BC: Primary Results from the Randomized Phase III TROPION-Breast01 Trial

Expert oncologist Aditya Bardia, MD, reflects on data from the TROPION-Breast01 trial of dato-DXd versus chemotherapy in metastatic HR+/HER2– breast cancer following ESMO 2023.

Aditya bardiaDatopotamab deruxtecanPrimary resultsRandomized phasePreviously treated inoperableMetastatic hormone receptor positiveBreast cancerMetastatic breast cancerHr positiveHer2 negativeTropion breast01Dato dxdEfficacy dataSafety dataAdverse eventsToxicity profile

vimarsana © 2020. All Rights Reserved.